Time-resolved fluorometry in the genetic diagnosis of familial defective apolipoprotein B-100

G. Eggertsen, M. Eriksson, O. Wiklund, A. Iitia, S. O. Olofsson, B. Angelin, Lars Berglund

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

A novel technique for screening point mutations has been developed for diagnosis of familial defective apolipoprotein (apo) B-100 (FDB). In FDB, an amino acid exchange occurs at position 3500 in apoB-100 due to a point mutation. Polymerase chain reaction (PCR) was performed on the appropriate region of the apoB gene, and the PCR products were hybridized in solution with europium-labeled oligonucleotides, complementary to either the wildtype or the mutant genome. The presence or absence of the apoB-3500 mutation was monitored by time-resolved fluorescence of the europium chelate. The method allows a larger number of samples to be processed simultaneously, and the detection system displays a high level of sensitivity without the hazards connected to the use of radioactivity. When 127 Swedish patients, clinically diagnosed as suffering from heterozygous familial hypercholesterolemia, were screened for the presence of the apoB-3500 mutation, two patients, unrelated to each other, were found to be heterozygotes. These patients are the first reported cases of FDB from Sweden, and the frequency rate observed among hypercholesterolemic patients, 1.6%, is in accordance with the figures reported for several other patient populations in Europe and the United States.

Original languageEnglish (US)
Pages (from-to)1505-1508
Number of pages4
JournalJournal of Lipid Research
Volume35
Issue number8
StatePublished - 1994
Externally publishedYes

Fingerprint

Apolipoprotein B-100
Fluorometry
Hyperlipoproteinemia Type II
Apolipoproteins B
Europium
Polymerase chain reaction
Genes
Point Mutation
Radioactivity
Reaction products
Oligonucleotides
Hazards
Screening
Polymerase Chain Reaction
Fluorescence
Mutation
Amino Acids
Heterozygote
Sweden
Genome

Keywords

  • DNA-amplification
  • hypercholesterolemia
  • serum lipoproteins
  • time-resolved fluorescence

ASJC Scopus subject areas

  • Endocrinology

Cite this

Eggertsen, G., Eriksson, M., Wiklund, O., Iitia, A., Olofsson, S. O., Angelin, B., & Berglund, L. (1994). Time-resolved fluorometry in the genetic diagnosis of familial defective apolipoprotein B-100. Journal of Lipid Research, 35(8), 1505-1508.

Time-resolved fluorometry in the genetic diagnosis of familial defective apolipoprotein B-100. / Eggertsen, G.; Eriksson, M.; Wiklund, O.; Iitia, A.; Olofsson, S. O.; Angelin, B.; Berglund, Lars.

In: Journal of Lipid Research, Vol. 35, No. 8, 1994, p. 1505-1508.

Research output: Contribution to journalArticle

Eggertsen, G, Eriksson, M, Wiklund, O, Iitia, A, Olofsson, SO, Angelin, B & Berglund, L 1994, 'Time-resolved fluorometry in the genetic diagnosis of familial defective apolipoprotein B-100', Journal of Lipid Research, vol. 35, no. 8, pp. 1505-1508.
Eggertsen G, Eriksson M, Wiklund O, Iitia A, Olofsson SO, Angelin B et al. Time-resolved fluorometry in the genetic diagnosis of familial defective apolipoprotein B-100. Journal of Lipid Research. 1994;35(8):1505-1508.
Eggertsen, G. ; Eriksson, M. ; Wiklund, O. ; Iitia, A. ; Olofsson, S. O. ; Angelin, B. ; Berglund, Lars. / Time-resolved fluorometry in the genetic diagnosis of familial defective apolipoprotein B-100. In: Journal of Lipid Research. 1994 ; Vol. 35, No. 8. pp. 1505-1508.
@article{c24324ccc84543edbd36ac8aa369ecde,
title = "Time-resolved fluorometry in the genetic diagnosis of familial defective apolipoprotein B-100",
abstract = "A novel technique for screening point mutations has been developed for diagnosis of familial defective apolipoprotein (apo) B-100 (FDB). In FDB, an amino acid exchange occurs at position 3500 in apoB-100 due to a point mutation. Polymerase chain reaction (PCR) was performed on the appropriate region of the apoB gene, and the PCR products were hybridized in solution with europium-labeled oligonucleotides, complementary to either the wildtype or the mutant genome. The presence or absence of the apoB-3500 mutation was monitored by time-resolved fluorescence of the europium chelate. The method allows a larger number of samples to be processed simultaneously, and the detection system displays a high level of sensitivity without the hazards connected to the use of radioactivity. When 127 Swedish patients, clinically diagnosed as suffering from heterozygous familial hypercholesterolemia, were screened for the presence of the apoB-3500 mutation, two patients, unrelated to each other, were found to be heterozygotes. These patients are the first reported cases of FDB from Sweden, and the frequency rate observed among hypercholesterolemic patients, 1.6{\%}, is in accordance with the figures reported for several other patient populations in Europe and the United States.",
keywords = "DNA-amplification, hypercholesterolemia, serum lipoproteins, time-resolved fluorescence",
author = "G. Eggertsen and M. Eriksson and O. Wiklund and A. Iitia and Olofsson, {S. O.} and B. Angelin and Lars Berglund",
year = "1994",
language = "English (US)",
volume = "35",
pages = "1505--1508",
journal = "Journal of Lipid Research",
issn = "0022-2275",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "8",

}

TY - JOUR

T1 - Time-resolved fluorometry in the genetic diagnosis of familial defective apolipoprotein B-100

AU - Eggertsen, G.

AU - Eriksson, M.

AU - Wiklund, O.

AU - Iitia, A.

AU - Olofsson, S. O.

AU - Angelin, B.

AU - Berglund, Lars

PY - 1994

Y1 - 1994

N2 - A novel technique for screening point mutations has been developed for diagnosis of familial defective apolipoprotein (apo) B-100 (FDB). In FDB, an amino acid exchange occurs at position 3500 in apoB-100 due to a point mutation. Polymerase chain reaction (PCR) was performed on the appropriate region of the apoB gene, and the PCR products were hybridized in solution with europium-labeled oligonucleotides, complementary to either the wildtype or the mutant genome. The presence or absence of the apoB-3500 mutation was monitored by time-resolved fluorescence of the europium chelate. The method allows a larger number of samples to be processed simultaneously, and the detection system displays a high level of sensitivity without the hazards connected to the use of radioactivity. When 127 Swedish patients, clinically diagnosed as suffering from heterozygous familial hypercholesterolemia, were screened for the presence of the apoB-3500 mutation, two patients, unrelated to each other, were found to be heterozygotes. These patients are the first reported cases of FDB from Sweden, and the frequency rate observed among hypercholesterolemic patients, 1.6%, is in accordance with the figures reported for several other patient populations in Europe and the United States.

AB - A novel technique for screening point mutations has been developed for diagnosis of familial defective apolipoprotein (apo) B-100 (FDB). In FDB, an amino acid exchange occurs at position 3500 in apoB-100 due to a point mutation. Polymerase chain reaction (PCR) was performed on the appropriate region of the apoB gene, and the PCR products were hybridized in solution with europium-labeled oligonucleotides, complementary to either the wildtype or the mutant genome. The presence or absence of the apoB-3500 mutation was monitored by time-resolved fluorescence of the europium chelate. The method allows a larger number of samples to be processed simultaneously, and the detection system displays a high level of sensitivity without the hazards connected to the use of radioactivity. When 127 Swedish patients, clinically diagnosed as suffering from heterozygous familial hypercholesterolemia, were screened for the presence of the apoB-3500 mutation, two patients, unrelated to each other, were found to be heterozygotes. These patients are the first reported cases of FDB from Sweden, and the frequency rate observed among hypercholesterolemic patients, 1.6%, is in accordance with the figures reported for several other patient populations in Europe and the United States.

KW - DNA-amplification

KW - hypercholesterolemia

KW - serum lipoproteins

KW - time-resolved fluorescence

UR - http://www.scopus.com/inward/record.url?scp=0028132576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028132576&partnerID=8YFLogxK

M3 - Article

VL - 35

SP - 1505

EP - 1508

JO - Journal of Lipid Research

JF - Journal of Lipid Research

SN - 0022-2275

IS - 8

ER -